Previous 10 | Next 10 |
2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...
2023-11-03 12:32:00 ET Summary Oct. nonfarm payrolls came in weaker than expected, unemployment rate ticked up to 3.9%. AI will likely make all jobs obsolete at some point in the future - Elon Musk. BofA releases two feast and famine charts from the broader market. L...
2023-11-03 12:14:31 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (...
2023-11-03 09:53:11 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (NASDAQ: TNO...
2023-11-03 08:04:12 ET Shares of Werewolf Therapeutics ( NASDAQ: HOWL ) added ~34% after announcing two partial remissions in an early-stage clinical program for WTX-124, one of its lead cancer candidates targeted at solid tumors. Citing early data, Watertown, Massachusetts-...
2023-11-03 08:01:37 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported, this morning, preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-12...
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the ...
2023-11-02 08:37:27 ET Losers: Confluent CFLT -34% after Q3 earning release . Remitly Global RELY -23% after Q3 earning release . Acurx Pharmaceuticals ( ACXP ) -18% announces positive top-line Ibezapolstat phase 2 efficacy results with 96% clinical c...
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation. Additional posters representing an expansive body of data demonstratin...
2023-10-30 08:34:25 ET Miromatrix Medical ( MIRO ) +225% to buy Miromatrix Medical for $3.25 per share, MIRO jumps 225%. TD Holdings ( BYU ) +63% . Conduit Pharmaceuticals ( CDT ) +56% . VYNE Therapeutics Inc ( VYNE ) +47% jumps 52% on posit...
News, Short Squeeze, Breakout and More Instantly...
Werewolf Therapeutics Inc. Company Name:
HOWL Stock Symbol:
NASDAQ Market:
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 - - Early WTX-330 dose-escalation data demonstrated encouraging clinical acti...
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...